The NRMX saga continues. Yesterday study data was presented by the company at a conference and they didn't quite know what to make of their own data: Neurochem Drugs Results Unclear, Researcher Says. That surely is a bad sign.
This morning Piper has reiterated its Underperform recommendation and lowered its target in NRMX to $4. The executive summary of Piper's report: Alzhemed is unlikely to be approved because it effect is small.